Clinical evidence in appetite regulation
Building the evidence base for mechanical satiety modulation
From foundational physiology to real-world observations — a structured, transparent, and progressive clinical development pathway.
Why investigate mechanical modulation of satiety?
Appetite regulation involves the integration of hormonal, neural, and mechanical signals. While pharmacological approaches targeting hormonal pathways (GLP-1 receptor agonists) have demonstrated significant clinical efficacy, the mechanical component of satiety — driven by gastric distension and abdominal mechanosensitivity — has received comparatively less attention as a clinical lever.
Yet foundational research spanning over seven decades has established that mechanical signals from the stomach are among the earliest and most potent determinants of meal termination. Crucially, Geliebter et al. (1986) demonstrated that these signals can be modulated by applying external abdominal pressure — reducing both intragastric pressure dynamics and food intake.
First real-world data: design and results
A prospective exploratory feasibility observation was conducted to evaluate the effect of the device on satiety perception, eating behaviors, weight changes, and tolerance. Participants were followed weekly by a dietitian and a patient expert.
Aggregate results
What the initial data tell us
Beyond the aggregate numbers, structured dietitian follow-up revealed qualitative patterns consistent across the majority of participants:
Earlier perception of fullness during meals. Reduced tolerance to large portions, even during periods without active device use. Mechanical satiety effect reported by over 80% of participants.
Disruption of automatic eating patterns. Reduction in emotional and sugar-related snacking. Educational effect on portion size and eating speed. Body-awareness anchoring — acting as a physical reminder during meals.
Motivational support: perception of progress, sense of control. Reinforcement of body image linked to tangible changes (belt size reduction). Maintained effects in some participants even during intermittent use.
Responder profile observations
The strongest and most consistent responses were observed in adults with overweight or moderate obesity (BMI 25–40), particularly those in post-dietary or post-pharmacological phases. Participants with disorganized eating behaviors (but without severe eating disorders) also showed meaningful engagement.
Conversely, reduced or absent effectiveness was observed in participants with severe obesity (BMI > 40), primarily due to morphological constraints affecting device fit and compression transfer. This finding supports the BMI < 40 indication boundary.
Tolerance
Overall tolerance was rated good to very good. No serious adverse events were reported. Minor discomforts included positional adjustment difficulty in some users and reduced comfort during warm weather. Device integration into daily activities was rated as easy by 82% of participants.
Registry GC-REG-01: structured observation in clinical practice
Building on the exploratory feasibility data, a prospective multicentric observational registry has been initiated to document the use of GASTER control® in routine medical practice under standardized conditions.
Scientific governance
A structured and transparent development pathway
Clinical evidence for GASTER control® is being built progressively, following a structured approach aligned with medical device development best practices.
Foundational literature
Healthcare professionals: full clinical information
GASTER control® — GASTER Technology Limited, 5/1 Merchants Street, Valletta VLT 1171, Malta. Proprietary biomechanical design (patent pending).